ATE215816T1 - Feste oral anzuwendende arzeneiform - Google Patents

Feste oral anzuwendende arzeneiform

Info

Publication number
ATE215816T1
ATE215816T1 AT96918678T AT96918678T ATE215816T1 AT E215816 T1 ATE215816 T1 AT E215816T1 AT 96918678 T AT96918678 T AT 96918678T AT 96918678 T AT96918678 T AT 96918678T AT E215816 T1 ATE215816 T1 AT E215816T1
Authority
AT
Austria
Prior art keywords
active ingredient
administration
plasma levels
delayed
readily soluble
Prior art date
Application number
AT96918678T
Other languages
English (en)
Inventor
Ubaldo Conte
Lauretta Maggi
Alberto Reiner
Original Assignee
Applied Pharma Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Pharma Res filed Critical Applied Pharma Res
Application granted granted Critical
Publication of ATE215816T1 publication Critical patent/ATE215816T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT96918678T 1995-06-09 1996-06-05 Feste oral anzuwendende arzeneiform ATE215816T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT95MI001223A IT1276689B1 (it) 1995-06-09 1995-06-09 Forma farmaceutica solida ad uso orale
PCT/EP1996/002495 WO1996041617A1 (en) 1995-06-09 1996-06-05 Solid pharmaceutical form for oral use

Publications (1)

Publication Number Publication Date
ATE215816T1 true ATE215816T1 (de) 2002-04-15

Family

ID=11371782

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96918678T ATE215816T1 (de) 1995-06-09 1996-06-05 Feste oral anzuwendende arzeneiform

Country Status (9)

Country Link
EP (1) EP0833618B1 (de)
KR (1) KR19990021897A (de)
AT (1) ATE215816T1 (de)
CA (1) CA2224267A1 (de)
DE (1) DE69620606T2 (de)
ES (1) ES2174073T3 (de)
IT (1) IT1276689B1 (de)
PT (1) PT833618E (de)
WO (1) WO1996041617A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486177B2 (en) 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
TW430561B (en) * 1995-12-20 2001-04-21 Gea Farmaceutisk Fabrik As Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet
US6638948B1 (en) * 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
DE19816070A1 (de) 1998-04-09 1999-10-14 Aventis Res & Tech Gmbh & Co Retardtablette hergestellt aus linearen wasserunlöslichen Polysacchariden
EP1064937A1 (de) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmazeutische Zusammensetzungen mit kontrollierten Freigabe enthaltend ein Hypnotikum mit kurzer Wirkung oder deren Salze
IT1313590B1 (it) * 1999-08-03 2002-09-09 Formenti Farmaceutici Spa Composizioni a rilascio controllato di acido acetilsalicilico.
DE19954421A1 (de) * 1999-11-12 2001-05-31 Lohmann Therapie Syst Lts Filmförmige Zubereitung zur biphasigen Freisetzung pharmakologisch wirksamer oder anderer Substanzen
KR100446829B1 (ko) * 2002-02-20 2004-09-04 한국유나이티드제약 주식회사 가용화된 피록시캄을 함유한 확산형 정제의 조성물 및그의 제조방법
AU2013267036B2 (en) * 2003-03-21 2016-05-26 Mcneil-Ppc, Inc. Non-steroidal anti-inflammatory drug dosing regimen
MXPA05010010A (es) 2003-03-21 2006-03-10 Johnson & Johnson Regimen de dosificacion de farmaco anti-inflamatorio no-esteroideo.
US20040186180A1 (en) 2003-03-21 2004-09-23 Gelotte Cathy K. Non-steroidal anti-inflammatory drug dosing regimen
GB0501809D0 (en) * 2005-01-28 2005-03-09 Pharmakodex Ltd Anti-migraine formulations
US20090028937A1 (en) * 2005-01-31 2009-01-29 Kyowa Hakko Kogyo Co., Ltd. Tablet comprising ornithine hydrochloride
CN102846585A (zh) 2006-03-28 2013-01-02 杰佛林制药公司 低剂量的双氯芬酸和β-环糊精的制剂
WO2009021127A2 (en) * 2007-08-07 2009-02-12 Neurogen Corporation Controlled released compositions
PL2190418T3 (pl) * 2007-08-15 2014-03-31 Mcneil Ppc Inc Sposób dawkowania ibuprofenu o natychmiastowym i długotrwałym uwalnianiu
MX2010004570A (es) 2008-02-08 2010-06-03 Colgate Palmolive Co Metodos para la produccion de sal.
BRPI0906452A2 (pt) 2008-02-08 2015-07-14 Colgate Palmolive Co Composição, dispositivo, método para produzir ou inibir a formação de cáries dentais, reduzir, reparar ou inibir as leões pré-cárie do esmalte, reduzir ou inibir a desmineralização e promover a remineralização dos dentes, reduzir a hipersensibilidade dos dentes, reduzir ou inibir a gengivite, promover a cura de feridas ou de cortes na boca, reduzir os níveis de bactérias que produzem ácido, aumentar os níveis relativos de bactérias arginolíticas, inibir a formação de composição, dispositivo, método para reduzir ou inibir a formação de cáries dentais, reduzir, reparar ou inibir as leões pré-cárie dp esmalte, reduzir ou inibir a desmineralização e promover a remineralização dos dentes, reduzir a hipersibilidade dos dentes, reduzir ou inibir a gengivite, promover a cura de feridas ou de cortes na boca, reduzir os níveis de bactérias que produzem ácido, aumentar os níveis relativos de bactérias arginolíticas, inibir a formação de biofilme microbiano na cavidade oral, elevar e/ou manter o ph da placa em níveis de pelos menos um ph de 5,5, reduzir o acúmulo de placa, tratar, aliviar ou reduzir a boca seca, limpar os dentes e a cavidade oral, reduzir a erosão, branquear os dentes, imunizar os dentes contra as bactérias cariogênicas, e/ ou promover a saúde sistêmica, incluindo a saúde cardiovascular, e, uso de um aminoácido básico
JP2011512406A (ja) * 2008-02-22 2011-04-21 ハナル バイオファーマ カンパニー リミテッド 複合製剤
WO2011075422A1 (en) 2009-12-18 2011-06-23 Colgate-Palmolive Company Methods for production of high concentration of arginine bicarbonate solution at high pressue
JP2013514362A (ja) 2009-12-18 2013-04-25 コルゲート・パーモリブ・カンパニー 低圧での重炭酸アルギニンの製造方法
KR101320802B1 (ko) * 2010-02-16 2013-10-23 주식회사 드림파마 방출 제어형 사포그릴레이트 염산염 함유 다층 정제
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
DK2688557T3 (da) 2011-03-23 2017-11-27 Ironshore Pharmaceuticals & Dev Inc Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
KR102124459B1 (ko) 2018-05-02 2020-06-23 주식회사 에코앤휴먼 종패 부착용 식생부 및 이를 포함하는 인공어초
CN110037994B (zh) * 2019-05-24 2022-04-12 中国药科大学 一种布洛芬速释缓释双层片及其制备方法
CN114983973B (zh) * 2022-05-31 2023-05-05 石家庄四药有限公司 一种乌拉地尔缓释胶囊及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806359A (en) * 1987-04-22 1989-02-21 Mcneilab, Inc. Iburprofen sustained release matrix and process
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
FI93924C (fi) * 1991-09-17 1995-06-26 Martti Lauri Antero Marvola Menetelmä säädellysti lääkeainetta vapauttavan valmisteen valmistamiseksi
US5609884A (en) * 1992-08-31 1997-03-11 G. D. Searle & Co. Controlled release naproxen sodium plus naproxen combination tablet
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata

Also Published As

Publication number Publication date
PT833618E (pt) 2002-09-30
DE69620606D1 (de) 2002-05-16
ITMI951223A1 (it) 1996-12-09
DE69620606T2 (de) 2002-10-24
WO1996041617A1 (en) 1996-12-27
EP0833618A1 (de) 1998-04-08
ITMI951223A0 (it) 1995-06-09
KR19990021897A (ko) 1999-03-25
ES2174073T3 (es) 2002-11-01
IT1276689B1 (it) 1997-11-03
CA2224267A1 (en) 1996-12-27
EP0833618B1 (de) 2002-04-10

Similar Documents

Publication Publication Date Title
ATE215816T1 (de) Feste oral anzuwendende arzeneiform
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
MY118371A (en) Tetrahydrolipstatin containing compositions
TW200505498A (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
ES2099275T3 (es) Comprimido multiparticulas de desleimiento rapido.
DK1117383T3 (da) Doseringsformer omfattende terapeutisk formulering
ATE370727T1 (de) Pharmazeutische suspensionstabletten- zusammenstellungen
AU2002231654A1 (en) Pharmaceutical paste comprising an acid-labile active ingredient
AP2003002763A0 (en) Controlled release formulations for oral administration
DE69815856D1 (de) Cefadroxilmonohydrat tablettenformulierung
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
SE8901003D0 (sv) Snabbloesliga preparat
CY1110184T1 (el) Φαρμακευτικη συνθεση για μαλακες καψουλες για χορηγηση απο το στομα η οποια περιεχει βινορελβινη και μεθοδος θεραπειας
NO962752L (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
MXPA06000332A (es) Nueva composicion farmaceutica solida que comprende amisulprida.
MXPA03011317A (es) Comprimido masticable que comprende paracetamol.
GR20010100377A (el) Φαρμακευτικη συνθεση περιεχουσα σιταλοπραμη
HUP0203148A2 (hu) Mirtazapint tartalmazó orálisan dezintegrálódó készítmény
HUP9901659A2 (hu) Flupirtin alkalmazása a hematopoetikus sejtrendszer károsodásával kapcsolatos megbetegedések megelőzésére és gyógyítására alkalmas gyógyszerkészítmény előállítására
ES2057021T3 (es) Un metodo de manufactura de una dosificacion farmaceutica solida en forma de triturado en tableta.
DE60024439D1 (de) Enalaprilmaleat enthaltende, stabile, feste arzneimittel
MY145885A (en) Controlled release formulations for oral administration
ECSP982396A (es) Composiciones que contienen tetrahidrolipstatina

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties